{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T20:18:17Z","timestamp":1770495497999,"version":"3.49.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n            <jats:title>Key Points<\/jats:title>\n            <jats:p>\n                                 <jats:list list-type=\"bullet\"><jats:list-item><jats:p>This is an updated meta-analysis about glucagon-like peptide-1 receptor agonists (GLP-1 RAs) incorporating findings from the recently published FLOW and SELECT studies.<\/jats:p><\/jats:list-item><jats:list-item><jats:p>Our findings show that GLP-1 RAs reduce kidney disease progression in patients with type 2 diabetes or overweight\/obesity status, with or without CKD.<\/jats:p><\/jats:list-item><jats:list-item><jats:p>Our meta-analysis supports the use of GLP-1 RAs for reducing the risk of adverse kidney outcomes across different populations.<\/jats:p><\/jats:list-item><\/jats:list>\n                              <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Recent data indicate a potential benefit of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on the progression of kidney disease among patients with CKD. Our aim was to evaluate the effect of GLP-1 RAs on the risk of worsening kidney function across different populations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We conducted a meta-analysis of randomized controlled trials that tested GLP-1 RA treatment versus placebo in individuals with type 2 diabetes or with overweight\/obesity status, with or without CKD, with kidney events reported as primary or secondary end points. The primary outcome was the occurrence of worsening kidney function, defined as either a doubling of serum creatinine or a \u226540% or \u226550% decline in eGFR, according to each study report. Secondary outcomes included development of persistent macroalbuminuria and a composite of worsening kidney function or the development of persistent macroalbuminuria. Subgroup analyses were performed by eGFR and albuminuria categories. The results are presented as risk ratios with 95% confidence intervals.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Eight trials were eligible, including a total of 68,572 patients, of whom 34,042 (49.6%) received GLP-1 RA treatment. During follow-up, 1028 participants receiving GLP-1 RA (3.0%) and 1150 participants receiving placebo (3.5%) experienced worsening kidney function. Treatment with GLP-1 RAs (versus placebo) resulted in a reduction in the risk of worsening kidney function (risk ratios, 0.84; 95% confidence interval, 0.77 to 0.91; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). In addition, treatment with GLP-1 RAs significantly reduced the risk of developing persistent macroalbuminuria and the risk of the composite outcome of worsening kidney function or development of persistent macroalbuminuria. The results were consistent in patients with and without CKD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>In conclusion, our meta-analysis suggests that GLP-1 RA reduce kidney disease progression in type 2 diabetes or overweight\/obesity regardless of CKD status.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Podcast<\/jats:title>\n            <jats:p>This article contains a podcast at https:\/\/www.asn-online.org\/media\/podcast\/CJASN\/2025_02_14_CJASNFeb20.2.2142025.mp3\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.2215\/cjn.0000000584","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T16:50:46Z","timestamp":1728406246000},"page":"159-168","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes"],"prefix":"10.2215","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1951-3941","authenticated-orcid":false,"given":"Lu\u00eds","family":"Mendon\u00e7a","sequence":"first","affiliation":[{"name":"Unit of Cardiovascular Research and Development - Unic@RISE, Department of Surgery and Physiology, Faculty of Medicine of University of Porto, Porto, Portugal"},{"name":"Department of Nephrology, ULS S\u00e3o Jo\u00e3o, Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0578-3982","authenticated-orcid":false,"given":"Henrique","family":"Moura","sequence":"additional","affiliation":[{"name":"Unit of Cardiovascular Research and Development - Unic@RISE, Department of Surgery and Physiology, Faculty of Medicine of University of Porto, Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8388-4312","authenticated-orcid":false,"given":"Paulo Castro","family":"Chaves","sequence":"additional","affiliation":[{"name":"Unit of Cardiovascular Research and Development - Unic@RISE, Department of Surgery and Physiology, Faculty of Medicine of University of Porto, Porto, Portugal"},{"name":"Department of Medicine, ULS S\u00e3o Jo\u00e3o, Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8173-8255","authenticated-orcid":false,"given":"Jo\u00e3o S\u00e9rgio","family":"Neves","sequence":"additional","affiliation":[{"name":"Unit of Cardiovascular Research and Development - Unic@RISE, Department of Surgery and Physiology, Faculty of Medicine of University of Porto, Porto, Portugal"},{"name":"Department of Endocrinology, Diabetes and Metabolism, ULS S\u00e3o Jo\u00e3o, Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2304-6138","authenticated-orcid":false,"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Unit of Cardiovascular Research and Development - Unic@RISE, Department of Surgery and Physiology, Faculty of Medicine of University of Porto, Porto, Portugal"},{"name":"Centre d'Investigations Cliniques Plurith\u00e9matique 1433 and Inserm U1116, CHRU Nancy, FCRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France"}]}],"member":"276","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"issue":"3","key":"B1-20250218","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41574-022-00776-2","article-title":"Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice","volume":"19","author":"Lim","year":"2023","journal-title":"Nat Rev Endocrinol."},{"issue":"5","key":"B2-20250218","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","author":"Rossing","year":"2022","journal-title":"Kidney Int."},{"issue":"1","key":"B3-20250218","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12933-021-01229-2","article-title":"The residual cardiorenal risk in type 2 diabetes","volume":"20","author":"Giugliano","year":"2021","journal-title":"Cardiovasc Diabetol."},{"issue":"8","key":"B4-20250218","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/dom.14707","article-title":"Effect of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: a meta-analysis of placebo-controlled randomized trials","volume":"24","author":"Leite","year":"2022","journal-title":"Diabetes Obes Metab."},{"issue":"1","key":"B5-20250218","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1210\/clinem\/dgad398","article-title":"Glucagon-like peptide-1 receptor agonists across the spectrum of heart failure","volume":"109","author":"Ferreira","year":"2023","journal-title":"J Clin Endocrinol Metab."},{"issue":"24","key":"B6-20250218","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med."},{"issue":"9","key":"B7-20250218","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1111\/dom.14776","article-title":"Effect of glucagon-like peptide 1 receptor agonists on albuminuria in adult patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"24","author":"Yuan","year":"2022","journal-title":"Diabetes Obes Metab."},{"issue":"2","key":"B8-20250218","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"New Engl J Med."},{"issue":"7","key":"B9-20250218","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","article-title":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","volume":"30","author":"Colhoun","year":"2024","journal-title":"Nat Med."},{"issue":"10193","key":"B10-20250218","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet."},{"issue":"4","key":"B11-20250218","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"New Engl J Med."},{"issue":"23","key":"B12-20250218","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"New Engl J Med."},{"issue":"19","key":"B13-20250218","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"New Engl J Med."},{"issue":"13","key":"B14-20250218","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"New Engl J Med."},{"issue":"10","key":"B15-20250218","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"New Engl J Med."},{"issue":"10","key":"B16-20250218","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"B17-20250218","doi-asserted-by":"crossref","first-page":"101366","DOI":"10.1016\/j.diabet.2022.101366","article-title":"Effect of glucagon-like peptide 1 receptor agonists on the renal protection in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"48","author":"Li","year":"2022","journal-title":"Diabetes Metab."},{"issue":"23","key":"B18-20250218","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med."},{"issue":"24","key":"B19-20250218","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med."},{"issue":"10","key":"B20-20250218","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","article-title":"Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial","volume":"30","author":"Mann","year":"2024","journal-title":"Nat Med."},{"key":"B21-20250218","doi-asserted-by":"crossref","first-page":"e078242","DOI":"10.1136\/bmj-2023-078242","article-title":"Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study","volume":"385","author":"Simms-Williams","year":"2024","journal-title":"bmj"},{"issue":"6","key":"B22-20250218","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jacc.2023.05.048","article-title":"GLP-1 receptor agonist therapy with and without SGLT2 inhibitors in patients with type 2 diabetes","volume":"82","author":"Neves","year":"2023","journal-title":"J Am Coll Cardiol."},{"key":"B23-20250218","doi-asserted-by":"crossref","first-page":"20420188221112490","DOI":"10.1177\/20420188221112490","article-title":"The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice","volume":"13","author":"von Scholten","year":"2022","journal-title":"Ther Adv Endocrinol Metab."},{"issue":"suppl 3","key":"B24-20250218","doi-asserted-by":"crossref","first-page":"gfac070.013","DOI":"10.1093\/ndt\/gfac070.013","article-title":"MO399: remodel: A mechanistic trial evaluating the effects of semaglutide on the kidneys in people with type 2 diabetes and chronic kidney disease","volume":"37","author":"Bjornstad","year":"2022","journal-title":"Nephrol Dial Transplant."},{"issue":"3","key":"B25-20250218","doi-asserted-by":"crossref","first-page":"e221169","DOI":"10.1001\/jamanetworkopen.2022.1169","article-title":"Association of glucagon-like peptide-1 receptor agonist vs dipeptidyl peptidase-4 inhibitor use with mortality among patients with type 2 diabetes and advanced chronic kidney disease","volume":"5","author":"Chen","year":"2022","journal-title":"JAMA Netw Open."},{"issue":"7","key":"B26-20250218","doi-asserted-by":"crossref","first-page":"e2421305","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open."},{"issue":"1","key":"B27-20250218","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/dom.14551","article-title":"Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss","volume":"24","author":"Wharton","year":"2022","journal-title":"Diabetes Obes Metab."},{"issue":"6","key":"B28-20250218","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.survophthal.2023.07.002","article-title":"GLP-1 receptor agonists and diabetic retinopathy: a meta-analysis of randomized clinical trials","volume":"68","author":"Kapoor","year":"2023","journal-title":"Surv Ophthalmol."},{"issue":"9","key":"B29-20250218","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/ndt\/gfv269","article-title":"Glomerular filtration rate decline as a surrogate end point in kidney disease progression trials","volume":"31","author":"Badve","year":"2016","journal-title":"Nephrol Dial Transplant."}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.2215\/CJN.0000000584","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T19:01:08Z","timestamp":1739905268000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.2215\/CJN.0000000584"}},"subtitle":["A Meta-Analysis of Randomized Placebo-Controlled Trials"],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.0000000584","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]},"assertion":[{"value":"2024-06-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}